Long-Term Effectiveness of Upadacitinib in Difficult-to-Treat Psoriatic Arthritis: A 104-week Real-World Clinical and Ultrasound Study
Psoriasis: Targets and Therapy · 2026-07 · Volume 16 · 1-9
DOI: 10.2147/ptt.s611459 ↗Kurz gefasst
Fachartikel in der Zeitschrift Psoriasis: Targets and Therapy, 2026-07. Verfasst von D Graceffa und 6 weiteren Autor:innen. Beteiligte Einrichtung: UOC Experimental Clinical Dermatology, San Gallicano Dermatological Institute, IRCCS, Rome, Italy. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- UOC Experimental Clinical Dermatology, San Gallicano Dermatological Institute, IRCCS, Rome, Italy.
- UOSD Clinical Trial Center and Biostatistic, San Gallicano Dermatological Institute, IRCCS, Rome, Italy.
- Scientific Direction, San Gallicano Dermatological Institute, IRCCS, Rome, Italy.
Zitieren
APA
Graceffa, D., Sperati, F., Fargnoli, M. C., Cameli, N., Pacifico, A., Demofonte, I., & Lora, V. (2026). Long-Term Effectiveness of Upadacitinib in Difficult-to-Treat Psoriatic Arthritis: A 104-week Real-World Clinical and Ultrasound Study. Psoriasis: Targets and Therapy, Volume 16, 1-9. https://doi.org/10.2147/ptt.s611459
Vancouver
Graceffa D, Sperati F, Fargnoli MC, Cameli N, Pacifico A, Demofonte I, et al. Long-Term Effectiveness of Upadacitinib in Difficult-to-Treat Psoriatic Arthritis: A 104-week Real-World Clinical and Ultrasound Study. Psoriasis: Targets and Therapy. 2026;Volume 16:1-9. doi:10.2147/ptt.s611459
BibTeX
@article{Graceffa2026,
author = {Graceffa, D and Sperati, F and Fargnoli, M C and Cameli, N and Pacifico, A and Demofonte, I and Lora, V},
title = {Long-Term Effectiveness of Upadacitinib in Difficult-to-Treat Psoriatic Arthritis: A 104-week Real-World Clinical and Ultrasound Study},
journal = {Psoriasis: Targets and Therapy},
year = {2026},
volume = {Volume 16},
pages = {1--9},
doi = {10.2147/ptt.s611459}
}
EUVIMED